Pfizer (PFE) Gains from Sales and Divestitures (2010 - 2011)
Pfizer (PFE) posted quarterly Gains from Sales and Divestitures of $13.3 million for Q4 2011, up 17126.92% YoY from N/an in Q4 2010, and up 17126.92% sequentially from -$78000.0 in Q4 2010.
Pfizer (PFE) Gains from Sales and Divestitures (2010 - 2011) Analysis & Trends
Pfizer has disclosed Gains from Sales and Divestitures across 2 years of filings, most recently posting $13.3 million for Q4 2011.
- In Q4 2011, Gains from Sales and Divestitures rose 17126.92% year-over-year to $13.3 million; the TTM figure through Dec 2011 stood at $13.3 million (up 17126.92% YoY), while the FY2011 annual figure was $13.3 million, up 17126.92% from the prior year.
- Gains from Sales and Divestitures grew to $13.3 million in Q4 2011, from -$78000.0 in the prior quarter.
- Over the last five years, Gains from Sales and Divestitures for PFE reached as high as $13.3 million in Q4 2011 and fell as low as -$78000.0 in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2011 | 13.28 Mn |
| Dec 31, 2011 | 13.28 Mn |
| Dec 31, 2010 | -78,000.00 |
| Dec 31, 2010 | -78,000.00 |